A pharmaceutical composition for treating non-alcoholic fatty liver and its preparation method and application

Abstract

The invention discloses a food, health product and medicinal composition for treating the non-alcoholic fatty liver disease, which is a preparation prepared from the following raw material medicines by weight: 20 to 40 parts of raw fructus crataegi, 20 to 40 parts of scorched fructus crataegi, 10 to 30 parts of medicated leaven, 10 to 20 parts of rhizoma atractylodis macrocephalae, 10 to 30 parts of folium nelumbinis, 5 to 15 parts of rhizoma alismatis, 10 to 20 parts of rhizoma curcumae longae, 5 to 15 parts of cassiae semen, and 3 to 9 parts of rhizoma coptidis. The invention further discloses a preparation method and application of the composition. The medicinal composition disclosed by the invention can effectively treat the non-alcoholic fatty liver disease, and has a wide application prospect.

Description

Technical field

[0001] The invention relates to a pharmaceutical composition for treating non-alcoholic fatty liver and its preparation method and application. Background technique

[0002] Non-alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function enzymes and chronic liver disease in Western developed countries such as Europe and the United States, including non-alcoholic simple fatty liver (NAFL). ), non-alcoholicsteatohepatitis (NASH) and related liver cirrhosis and hepatocellular carcinoma. The prevalence of NAFLD in ordinary adults is 20% to 33%, of which NASH and liver cirrhosis account for 10% to 20% and 2% to 3%, respectively. The prevalence of NAFL in obese patients is 60% to 90% (where NASH is 20% to 25%, and liver cirrhosis is 2% to 8%). The prevalence of NAFLD in patients with type 2 diabetes and hyperlipidemia is 28%, respectively ~55% and 27%~92%, in the body mass index> 30kg / m 2 Up to 80% of the population. In recent years, ...

Images